Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 51% above its 5-year average of 0.01, near the high end of its 5-year range (-1.51–0.15).
As of the fiscal period ended Tuesday, June 30, 2026. 101.92% above its 12-month average of -0.51.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
-0.51
DEBT TO EQUITY RATIO AVG 3Y
0.01
DEBT TO EQUITY RATIO AVG 5Y
0.01
DEBT TO EQUITY RATIO AVG 10Y
0.00
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+101.92%
CURRENT VS 3Y AVG
-21.70%
CURRENT VS 5Y AVG
+50.54%
CURRENT VS 10Y AVG
+707.05%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 771 covered companies
CURRENT VS SECTOR MEDIAN
-91.09%
vs the sector median at left
Artelo Biosciences, Inc.
Market Cap
$1.37M
Debt to Equity Ratio
0.01
TTM Avg
-0.51
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.39M
Debt to Equity Ratio
N/A
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$1.43M
Debt to Equity Ratio
0.24
TTM Avg
0.63
3Y Avg
2.77
5Y Avg
1.75
Market Cap
$1.47M
Debt to Equity Ratio
0.83
TTM Avg
0.17
3Y Avg
0.16
5Y Avg
0.13
Market Cap
$1.48M
Debt to Equity Ratio
0.02
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | $1.37M | 0.01 | -0.51 | 0.01 | 0.01 |
| Genprex, Inc. (GNPX)vs › | $1.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.39M | N/A | 0.05 | 0.05 | 0.05 |
| NewcelX Ltd. (NCEL)vs › | $1.34M | 0.06 | 0.03 | 0.02 | 0.01 |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | 0.24 | 0.63 | 2.77 | 1.75 |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | 1.51 | 0.59 | 0.51 | 3.40 |
| Curis, Inc. (CRIS)vs › | $1.46M | 0.22 | 0.30 | 0.17 | 0.13 |
| PMGC Holdings Inc. (ELAB)vs › | $1.47M | 0.83 | 0.17 | 0.16 | 0.13 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | 0.02 | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.21M | 0.05 | 0.07 | 0.07 | 0.07 |
Debt/Equity
0.01
Current Ratio
3.00
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.11 |
| 2025-12-31 | -0.53 |
| 2025-09-30 | -1.51 |
| 2025-06-30 | -0.62 |
| 2025-03-31 | 0.15 |
| 2024-12-31 | 0.04 |
| 2024-09-30 | 0.02 |
| 2024-06-30 | 0.02 |
| 2024-03-31 | 0.01 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-11-30 | 0.00 |
| 2021-08-31 | 0.01 |
| 2021-05-31 | 0.00 |
| 2021-02-28 | 0.00 |
| 2020-11-30 | 0.00 |
| 2020-08-31 | 0.00 |
| 2020-05-31 | 0.00 |
| 2020-02-29 | 0.00 |
| 2019-11-30 | 0.00 |
| 2019-08-31 | 0.00 |
| 2019-05-31 | 0.00 |
| 2019-02-28 | 0.00 |
| 2018-11-30 | 0.00 |
| 2018-08-31 | 0.00 |
| 2018-05-31 | 0.00 |
| 2018-02-28 | 0.00 |
| 2017-11-30 | 0.00 |
| 2017-08-31 | 0.00 |
| 2017-05-31 | -0.26 |
| 2017-02-28 | -1.52 |
| 2016-11-30 | 0.00 |
| 2016-08-31 | 0.00 |
| 2016-05-31 | 0.00 |
| 2016-02-29 | 0.00 |
| 2015-11-30 | 0.00 |
| 2015-08-31 | 0.00 |
| 2015-05-31 | 0.00 |
| 2015-02-28 | 0.00 |
| 2014-11-30 | 0.00 |
| 2014-08-31 | 0.00 |
| 2014-05-31 | 0.00 |
| 2014-02-28 | 0.00 |
| 2013-11-30 | 0.00 |
